CIRCULOGENE’s OncoGenLDx next generation sequencing (NGS) panel includes NCCN guideline markers, as well as expert recommended actionable mutations across 486 DNA biomarkers and 72 RNA fusions.
The OncoGenLDx NGS panel provides a comprehensive molecular profile to help your doctor prescribe targeted treatment at diagnosis, understand your response to treatment, and monitor cancer progression and recurrence.
CIRCULOGENE offers the ONLY liquid cfRNA PD-L1, Plasma cfRNA PD-L1. Patients with PD-L1 have been known to respond positively to immunotherapy versus chemotherapy. Should you have a PD-L1 expression, your doctor will consider this with other markers and your overall health in order to determine the right treatment for you.
CIRCULOGENE’s OncoGenDx is a validated, multi-modal tumor profiling solution powered by Roche’s AVENIO sequencing chemistry and FoundationOne’s tertiary bioinformatics engine. The platform integrates DNA sequencing across 335 genes, RNA fusion detection for 72 genes, and PD-L1 IHC with CPS scoring.
The OncoGenDx tissue CGP platform delivers comprehensive molecular and immune biomarker data in a single unified report to help your doctor identify actionable mutations, select targeted therapies, and make informed treatment decisions for solid tumors including NSCLC and other thoracic malignancies.
CIRCULOGENE also offers testing for the presence of hereditary genes passed on from parents to offspring. These inherited genes play an important role in cancer risk and susceptibility.
